MediciNova Initiates Phase II Trial on Insomnia Pill
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics by ruth on January 25, 2007

MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorderMediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries.(GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of mutagenicity, antigenicity or carcinogenicity. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
Source: MediciNova
Permalink: MediciNova Initiates Phase II Trial on Insomnia Pill
Tags:
insomnia sleep sleeping+disorders MediciNova biotech phase+trial insomnia+pill trial+insomnia
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/50678







